Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

The drug company said Wednesday that it planned to file lawsuits against US businesses that sell retatrutide products illegally, and it’s asking regulators to do more to rein in…